Cargando…

Direct oral anti-Xa anticoagulants versus warfarin in newly diagnosed atrial fibrillation and CKD: the Korean National Health Insurance Data

INTRODUCTION: Despite the benefits of direct oral anti-Xa anticoagulants (DOACs), the risk–benefit profile of DOAC therapy compared to warfarin therapy in patients with non-valvular atrial fibrillation (AF) and chronic kidney disease (CKD), including end-stage renal disease (ESRD), is uncertain. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kee, Youn Kyung, Jeon, Hee Jung, Oh, Jieun, Yoo, Tae-Hyun, Kang, Dongwoo, Lee, Jungkuk, Shin, Dong Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541953/ https://www.ncbi.nlm.nih.gov/pubmed/37786900 http://dx.doi.org/10.3389/fmed.2023.1212816

Ejemplares similares

Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3–G5D
por: Welander, Frida, et al.
Publicado: (2023)

Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation
por: Williams, Brent A., et al.
Publicado: (2017)

ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation
por: Kaba, Riyaz A, et al.
Publicado: (2013)

Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States
por: Jain, Rahul, et al.
Publicado: (2018)

Quality of Anticoagulation with Warfarin in Korean Patients with Atrial Fibrillation and Prior Stroke: A Multicenter Retrospective Observational Study
por: Hong, Keun-Sik, et al.
Publicado: (2017)

Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban
por: Lip, Gregory Y. H., et al.
Publicado: (2018)

Safety and Effectiveness of Direct Oral Anticoagulants vs. Warfarin in Patients With Atrial Fibrillation and Endoscopy-Diagnosed Peptic Ulcer
por: Wang, Chun-Li, et al.
Publicado: (2021)

Comparative analysis and meta-analysis of major clinical trials with oral factor Xa inhibitors versus warfarin in atrial fibrillation
por: Nunes, José Pedro L, et al.
Publicado: (2014)

Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation
por: de Padua Mansur, Antonio, et al.
Publicado: (2012)

Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation
por: Choi, Jiyoon C, et al.
Publicado: (2014)

Veterans Perceptions of Satisfaction and Convenience with Anticoagulants for Atrial Fibrillation: Warfarin versus Direct Oral Anticoagulants
por: Mull, Hillary J, et al.
Publicado: (2020)

Trajectories of Oral Anticoagulation Adherence Among Medicare Beneficiaries Newly Diagnosed With Atrial Fibrillation
por: Hernandez, Inmaculada, et al.
Publicado: (2019)

Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation
por: Fox, Keith A. A., et al.
Publicado: (2020)

Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction
por: Szummer, Karolina, et al.
Publicado: (2017)

Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)
por: Connolly, Stuart J., et al.
Publicado: (2013)

Warfarin anticoagulation in hemodialysis patients with atrial fibrillation: comparison of nephrologist-led and anticoagulation clinic-led management
por: Bahbahani, Hamad, et al.
Publicado: (2018)

Incidence and predictors of excessive warfarin anticoagulation in patients with atrial fibrillation—The EWA study
por: Jaakkola, Samuli, et al.
Publicado: (2017)

Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin
por: Pundi, Krishna N., et al.
Publicado: (2021)

Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation
por: Yoo, Seo Yeon, et al.
Publicado: (2022)

Sex Differences in Oral Anticoagulation and Outcomes of Stroke and Intracranial Bleeding in Newly Diagnosed Atrial Fibrillation
por: Yong, Celina M., et al.
Publicado: (2020)

Trends in Use of Oral Anticoagulants in Older Adults With Newly Diagnosed Atrial Fibrillation, 2010-2020
por: Ko, Darae, et al.
Publicado: (2022)

Early Experience of Novel Oral Anticoagulants in Catheter Ablation for Atrial Fibrillation: Efficacy and Safety Comparison to Warfarin
por: Shin, Dong Geum, et al.
Publicado: (2016)

Atrial fibrillation bleeding risk and prediction while treated with direct oral anticoagulants in warfarin‐naïve or warfarin‐experienced patients
por: Perino, Alexander C., et al.
Publicado: (2022)

Stability of High‐Quality Warfarin Anticoagulation in a Community‐Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
por: Dallalzadeh, Liane O., et al.
Publicado: (2016)

The Costs of Warfarin Underuse and Nonadherence in Patients with Atrial Fibrillation: A Commercial Insurer Perspective
por: Casciano, Julian P., et al.
Publicado: (2013)

Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
por: Krejczy, Martin, et al.
Publicado: (2015)

Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valve Replacement or Repair
por: Mentias, Amgad, et al.
Publicado: (2022)

Effect of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Newly Diagnosed Cancer
por: Kim, Kyu, et al.
Publicado: (2018)

Efficacy and safety of warfarin in patients with non-valvular atrial fibrillation and CKD G3–G5D
por: Welander, Frida, et al.
Publicado: (2022)

Control of Anticoagulation Therapy in Patients with Atrial Fibrillation Treated with Warfarin: A Study from the Chinese Atrial Fibrillation Registry
por: Liang, Hai-Feng, et al.
Publicado: (2019)

Real-world comparison of non-vitamin K antagonist oral anticoagulants and warfarin in Asian octogenarian patients with atrial fibrillation
por: Kwon, Chang Hee, et al.
Publicado: (2016)

Should we shift warfarin to non-vitamin K antagonist oral anticoagulants for patients with atrial fibrillation staying well on warfarin for years?
por: Chao, T, et al.
Publicado: (2023)

Hospital Admissions, Costs, and 30-Day Readmissions Among Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran Etexilate or Warfarin
por: Fonseca, Eileen, et al.
Publicado: (2015)

Medical Costs of Oral Anticoagulants vs Warfarin for Atrial Fibrillation Patients with Different Stroke Risks
por: Deitelzweig, Steve, et al.
Publicado: (2013)

Switching warfarin to direct oral anticoagulants in atrial fibrillation: Insights from the NCDR PINNACLE registry
por: Sciria, Christopher T., et al.
Publicado: (2020)

Changing trends in the use of novel oral anticoagulants and warfarin for treating non-valvular atrial fibrillation
por: Birkinshaw, Alexander, et al.
Publicado: (2020)

Is the Risk of Diabetes Lower in Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulant Compared to Warfarin?
por: Liu, Xuyang, et al.
Publicado: (2022)

Trends in Oral Anticoagulation Therapy Among Korean Patients With Atrial Fibrillation: The KORean Atrial Fibrillation Investigation
por: Shin, Hong-Won, et al.
Publicado: (2012)

Determinants of label non-adherence to non-vitamin K oral anticoagulants in patients with newly diagnosed atrial fibrillation
por: Seelig, J, et al.
Publicado: (2022)

Correction to: Efficacy and safety of warfarin in patients with non-valvular atrial fibrillation and CKD G3–G5D
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9cn7du3eqbsj7l4j5kpu8r8rql